QURE241220P21000
- 0.00
- 0.000.00%
uniQure NV Newsroom
Notable Analyst Calls This Week: AMD, Adobe and Utilities Stocks Among Top Picks
Uniqure Insider Sold Shares Worth $1,503,000, According to a Recent SEC Filing
UniQure Is Maintained at Neutral by Goldman Sachs
Guggenheim Reiterates Buy on UniQureto Buy
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Raises Target Price to $20
UniQure Is Maintained at Outperform by RBC Capital
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $8.69 to $58
Express News | Uniqure NV : Leerink Partners Raises Target Price to $44 From $26
Sector Update: Health Care Stocks Decline Late Afternoon
UniQure Gets Rating Upgrade From Wells Fargo After Agreement With FDA -- Shares Continue Rally
Top Midday Gainers
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings
UniQure Price Target Raised to $52.00/Share From $20.00 by Raymond James
UniQure Raised to Strong Buy From Outperform by Raymond James
UniQure Stock Rockets 90% on FDA Update for AMT-130
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
Cantor Fitzgerald Maintains Overweight on UniQure, Raises Price Target to $58
Dow Falls 150 Points; Oracle Posts Downbeat Results
Express News | uniQure NV surged over 120% during Regular Trading Hours and triggered a circuit breaker. Previously, the company reached an agreement with the FDA on a plan to develop a treatment method for Huntington's disease.